Mangoceuticals (MGRX) Operating Expenses (2023 - 2026)

Mangoceuticals (MGRX) has 4 years of Operating Expenses data on file, last reported at $3.2 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 31.97% year-over-year to $3.2 million; the trailing twelve-month figure through Mar 2026 stood at $16.5 million (up 57.73% YoY), and the FY2025 full-year result was $18.3 million, up 118.9% from the prior year.
• Operating Expenses grew to $3.2 million in Q1 2026, from $415214.0 in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $7.6 million in Q3 2025 to a low of $415214.0 in Q4 2025.
• A 4-year average of $3.0 million and a median of $2.5 million in 2024 frame the typical range for Operating Expenses.
• Peak annual rise in Operating Expenses reached 312.54% in 2025, while the deepest fall reached 76.38% in 2025.
• Tracing MGRX's Operating Expenses over 4 years: stood at $2.7 million in 2023, then slumped by 35.15% to $1.8 million in 2024, then plunged by 76.38% to $415214.0 in 2025, then soared by 659.93% to $3.2 million in 2026.
• Business Quant data shows MGRX's Operating Expenses at $3.2 million in Q1 2026, $415214.0 in Q4 2025, and $7.6 million in Q3 2025.